Evidence map›Paper›PMID 34229737›Full record

ArticleOrphanet journal of rare diseases2021

Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA).

Matthias Sauter, Elena Belousova, Mirjana P Benedik, Tom Carter, Vincent Cottin, Paolo Curatolo, Maria Dahlin, Lisa D'Amato, Guillaume B d'Augères, Petrus J de Vries and 20 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Chromophobe thyroid carcinoma: a distinct entity associated with TSC gene alterations.Virchows Archiv : an international journal of pathology · 2026
    Review
  7. Review
  8. Article
  9. Mortality in Tuberous Sclerosis Complex in the United Kingdom, 2016-2022.Journal of intellectual disability research : JIDR · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 20 countries.

Matthias SauterKlinikum Kempten, Klinikverbund Allgäu, Robert-Weixler-Str. 50, 87439, Kempten, Germany. Matthias.Sauter@klinikverbund-allgaeu.de.ORCID 0000-0002-0583-3138
Elena BelousovaResearch and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russian Federation.
Mirjana P BenedikSPS Pediatrična Klinika, Ljubljana, Slovenia.
Tom CarterTSA Tuberous Sclerosis Association, Nottingham, UK.
Vincent CottinHôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France.
Paolo CuratoloTor Vergata University Hospital, Rome, Italy.
Maria DahlinKarolinska University Hospital, Stockholm, Sweden.
Lisa D'AmatoNovartis Farma S.P.A, Origgio, Italy.
Guillaume B d'AugèresAssociation Sclérose Tubéreuse de Bourneville, Gradignan, France.
Petrus J de VriesDivision of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa.
José C FerreiraCentro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
Martha FeuchtUniversitätsklinik Für Kinder-Und Jugendheilkunde (Affiliated Partner of the ERN EpiCARE), Vienna, Austria.
Carla FladrowskiAssociazione Sclerosi Tuberosa ONLUS, Milan, Italy.
Christoph HertzbergVivantes-Klinikum Neukölln, Berlin, Germany.
Sergiusz JozwiakDepartment of Child Neurology, Medical University of Warsaw, Warsaw, Poland.
John A LawsonThe Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia.
Alfons MacayaHospital Universitari Vall D'Hebron, Barcelona, Spain.
Ruben MarquesNovartis Farma S.P.A, Origgio, Italy.
Rima NabboutDepartment of Pediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.
Finbar O'CallaghanInstitute of Child Health, University College London, London, UK.
Jiong QinDepartment of Pediatrics, Peking University People's Hospital, Beijing, China.
Valentin SanderTallinn Children Hospital, Tallinn, Estonia.
Seema ShahNovartis Healthcare Pvt. Ltd, Hyderabad, India.
Yukitoshi TakahashiNational Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Aoi-ku, UrushiyamaShizuoka, Japan.
Renaud TouraineDepartment of Genetics, CHU-Hôpital Nord, Saint Etienne, France.
Sotiris YouroukosSt. Sophia Children's Hospital, Athens, Greece.
Bernard ZonnenbergUniversity Medical Center, Utrecht, The Netherlands.
Anna JansenPediatric Neurology Unit, Department of Pediatrics, UZ Brussel VUB, Brussels, Belgium.
J Chris KingswoodCardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, UK.
TOSCA investigators
Novartis (Italy) · ITKarolinska University Hospital · SEKempten University of Applied Sciences · DEPirogov Russian National Research Medical University · RUSydney Children's Hospital · AUUniversité Paris Cité · FRAssociazione Italiana Sclerosi Multipla · ITCentro Hospitalar de Lisboa Ocidental · PTChildren's Hospital Agia Sophia · GRHôpital Nord · FRMedical University of Warsaw · PLNational Epilepsy Center · JPNovartis (India) · INOčesna Klinika UKC Ljubljana · SIPeking University · CNSt George's, University of London · GBTallinn Health Care College · EETuberous Sclerosis Association · GBUniversitair Ziekenhuis Brussel · BEUniversitätsklinik für Kinder und Jugendpsychiatrie · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant disorder caused by pathogenic variants in either the TSC1 or TSC2 gene. Common manifestations of TSC have been grouped into major and minor clinical diagnostic criteria and assessed in clinical routine workup. However, case studies point towards the existence of rare disease manifestations and to the potential association of TSC with malignant tumors. In this study we sought to characterize rare manifestations and malignancies using a large cohort of patients.

methodsTuberOus SClerosis registry to increAse disease awareness (TOSCA) is a multicenter, international disease registry collecting clinical manifestations and characteristics of patients with TSC, both retrospectively and prospectively. We report rates and characteristics of rare manifestations and malignancies in patients with TSC who had enrolled in the TOSCA registry. We also examined these manifestations by age, sex, and genotype (TSC1 or TSC2).

resultsOverall, 2211 patients with TSC were enrolled in the study. Rare manifestations were reported in 382 (17.3%) study participants and malignancies in 65 (2.9%). Of these rare manifestations, the most frequent were bone sclerotic foci (39.5%), scoliosis (23%), thyroid adenoma (5.5%), adrenal angiomyolipoma (4.5%), hemihypertrophy and pancreatic neuroendocrine tumors (pNET; both 3.1%). These rare manifestations were more commonly observed in adults than children (66.2% vs. 22.7%), in females versus males (58.4% vs. 41.6%; except for scoliosis: 48.9% vs. 51.1%), and in those with TSC2 versus TSC1 (67.0% vs. 21.1%; except for thyroid adenoma: 42.9% vs. 57.1%). In the 65 individuals with reported malignancies, the most common were renal cell carcinoma (47.7%), followed by breast (10.8%) and thyroid cancer (9.2%). Although malignancies were more common in adult patients, 26.1% were reported in children and 63.1% in individuals < 40 years. TSC1 mutations were over-represented in individuals with malignancies compared to the overall TOSCA cohort (32.1% vs. 18.5%).

conclusionRare manifestations were observed in a significant proportion of individuals with TSC. We recommend further examination of rare manifestations in TSC. Collectively, malignancies were infrequent findings in our cohort. However, compared to the general population, malignant tumors occurred earlier in age and some tumor types were more common.

Indexed as

Adrenal Gland NeoplasmsAngiomyolipomaTuberous SclerosisAdultChildFemaleHumansMaleMutationRegistriesRetrospective StudiesTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinMalignancyRare manifestationTOSCATSCTuberous sclerosis complex

Identifiers

PMID34229737
PMCPMC8259106
OpenAlexW3128606617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.